{"id":"tegafur-ugotex-or-capecitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hand-foot syndrome"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Stomatitis"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tegafur is a prodrug of 5-fluorouracil (5-FU) that is converted in the body to active 5-FU, which inhibits thymidylate synthase and disrupts nucleotide synthesis. Uracil is a competitive inhibitor of dihydropyrimidine dehydrogenase, the enzyme that degrades 5-FU, thereby prolonging 5-FU exposure and enhancing its cytotoxic effects. This combination allows for oral administration with improved bioavailability compared to intravenous 5-FU.","oneSentence":"Tegafur-Uracil (Tegafur-Ugotex) is a combination prodrug that inhibits thymidylate synthase to block DNA synthesis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:25.398Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Gastric cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT07161453","phase":"PHASE4","title":"Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2025-09-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9152,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tegafur-Ugotex or Capecitabine","genericName":"Tegafur-Ugotex or Capecitabine","companyName":"Liaoning Cancer Hospital & Institute","companyId":"liaoning-cancer-hospital-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tegafur-Uracil (Tegafur-Ugotex) is a combination prodrug that inhibits thymidylate synthase to block DNA synthesis in cancer cells. Used for Colorectal cancer, Gastric cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}